Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study

Annals of Allergy, Asthma and Immunology

Volumn 104, Issue 3, 2010, Pages 259-267

  Segall, Nathan ^a   Gawchik, Sandra ^b   Georges, George ^c   Haeusler, Jean Marc C ^d  

^a Clinical Research Atlanta   (United States)

^b Asthma and Allergy Research Associates   (United States)

^c SANOFI   (France)

^d UCB Inc   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOCETIRIZINE; PLACEBO; POLLEN ANTIGEN;

ADULT; AGED; ARTICLE; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY THROAT; EPWORTH SLEEPINESS SCALE; EVENING DOSAGE; FATIGUE; FEMALE; GRASS POLLEN; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NASAL PRURITUS; NOSE CONGESTION; OCULAR PRURITUS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; RHINORRHEA; SCORING SYSTEM; SENSITIZATION; SNEEZING; SOMNOLENCE; SYMPTOM; TREATMENT OUTCOME; UNITED STATES; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT ALLERGY SPECIFIC QUESTIONNAIRE;

ADOLESCENT; ADULT; AGED; CETIRIZINE; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; MIDDLE AGED; PLACEBOS; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; UNITED STATES;

EID: 77649162797     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2009.12.003     Document Type: Article

References (33)

1. Airborne Allergens. Something in the Air (April 2003), National Institute of Allergy and Infectious Diseases, Bethesda, MD. http://www3.niaid.nih.gov/topics/allergicDiseases/PDF/airborne_allergens.pdf NIH publication 03-7045. Accessed August 24, 2009
2. Rhinitis and Sinusitis Statistics (2008), American Academy of Allergy, Asthma and Immunology, Milwaukee, WI. http://www.aaaai.org/media/statistics/allergy-statistics.asp#allergicrhinitis Accessed August 24, 2009
3. Settipane R.A. Rhinitis: a dose of epidemiological reality. Allergy Asthma Proc 24 (2003) 147-154
4. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 73 (1994) 35-39
5. Blaiss M.S. Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc 28 (2007) 393-397
6. Dalal A.A., Stanford R., Henry H., and Borah B. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol 101 (2008) 23-29
7. Medical Expenditure Panel Survey Statistical Brief 204. Allergic Rhinitis: Trends in Use and Expenditures, 2000 and 2005 (2008), Agency for Healthcare Research and Quality, Rockville, MD
8. Crystal-Peters J., Crown W.H., Goetzel R.Z., and Schutt D.C. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 6 (2000) 373-378
9. Task Force on Allergic Disorders. Promoting Best Practice: Raising the Standard of Care of Patients With Allergic Disorders: Executive Summary Report (1998), American Academy of Allergy, Asthma and Immunology, Milwaukee, WI
10. Nathan R.A. The burden of allergic rhinitis. Allergy Asthma Proc 28 (2007) 3-9
11. Bousquet J., Neukirch F., Bousquet P.J., et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 117 (2006) 158-162
12. Meltzer E.O., Nathan R.A., Seiner J.C., and Storms W. Quality of life and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 99 (1997) S815-S819
13. Stuck B.A., Czajkowski J., Hagner A.E., et al. Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol 113 (2004) 663-668
14. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 62 suppl 85 (2007) 9-16
15. Young T., Finn L., Kim H., and The University of Wisconsin Sleep and Respiratory Research Group. Nasal obstruction as a risk factor for sleep-disordered breathing. J Allergy Clin Immunol 99 (1997) S757-S762
16. Gillard M., Christophe B., Wels B., Peck M., Massingham R., and Chatelain P. H1 antagonists: receptor affinity versus selectivity. Inflamm Res 52 suppl 1 (2003) S49-S50
17. Grant J.A., Riethuisen J.M., Moulaert B., and DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 88 (2002) 190-197
18. Xyzal. [package insert] (2008), sanofi-aventis US LLC and UCB Inc, Bridgewater, NJ, and Smyrna, GA
19. Bachert C., Bousquet J., Canonica G.W., et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 114 (2004) 838-844
20. Juniper E.F., and Guyatt G.H. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21 (1991) 77-83
21. Juniper E.F., Guyatt G.H., Griffith L.E., and Ferrie P.J. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 98 (1996) 843-845
22. Reilly M., Zbrozek A.S., and Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4 (1992) 353-365
23. Reilly M.C., Tanner A., and Meltzer E.O. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clin Drug Investig 11 (1996) 278-288
24. Johns M.W. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14 (1991) 540-545
25. Johns M.W. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 15 (1992) 376-381
26. Nathan R.A. The pathophysiology, clinical impact, and management of nasal congestion in allergic rhinitis. Clin Ther 30 (2008) 573-586
27. Bousquet J., Demarteau N., Mullol J., van den Akker-van Marle M.E., Van Ganse E., and Bachert C. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 60 (2005) 788-794
28. Vandenplas O., D'Alpaos V., and Van Brussel P. Rhinitis and its impact on work. Curr Opin Allergy Clin Immunol 8 (2008) 145-149
29. Gandon J.M., and Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol 54 (2002) 51-58
30. Verster J.C., de Weert A.M., Bijtjes S.I.R., et al. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 169 (2003) 84-90
31. Leger D., Annesi-Maesano I., Carat F., et al. Allergic rhinitis and its consequences on quality of sleep: an unexplored area. Arch Intern Med 166 (2006) 1744-1748
32. Santos C.B., Pratt E.L., Hanks C., McCann J., and Craig T.J. Allergic rhinitis and its effect on sleep, fatigue, and daytime somnolence. Ann Allergy Asthma Immunol 97 (2006) 579-586
33. Woods L., and Craig T.J. The importance of rhinitis on sleep, daytime somnolence, productivity and fatigue. Curr Opin Pulm Med 12 (2006) 390-396